Antidepressants are drugs used for the treatment of depressive disorders including dysthymia, obsessive compulsive disorder, anxiety, chronic pain, eating disorders, and neuropathic pain. Depression is a medical disorder which is related to the brain. Symptoms of depression include feeling sad and tired, lacking energy, and having difficulty enjoying routine daily activities. According to CDC, depression affects about 1 in every 5 individuals in the U.S. According to WHO (World Health Organization), at present an estimated 350 million people worldwide are affected by depression. Depression affects 10% to 15% men and about 10% to 25% of women.
Get Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=19037
The antidepressants market has been segmented based on the drug classes commonly used for the treatment of various types of depressive disorders. There are different types of antidepressant drugs available in the market such as selective serotonin reuptake inhibitors (SSRI), serotonin and noradrenaline reuptake inhibitors (SNRI), noradrenaline reuptake inhibitors, tricyclic antidepressants (TCA), reversible inhibitors of monoamine oxidase A (RIMA), tetracyclic antidepressants, etc. The different types of antidepressants are used in the treatment of depressive disorders. The different classes of antidepressants are as effective as each other, but some patients respond better to one antidepressant compared to another antidepressant. Side effects can also be different between these groups of antidepressants. Different types of depression disorders include dysthymic disorder, postpartum depression, psychotic depression, major or clinical depressive disorder, and seasonal affective disorder.
Factors driving the antidepressants market are declining side effects and rising efficacy of drugs in various classes as well as growing geriatric population where rate of mental illness is higher. However, the overall antidepressants market growth would decrease due to patent expiry of key antidepressants, fragile pipeline of new drugs, increasing number of generic drug alternatives, and growing prevalence of treatment-resistant psychiatric disorders.